Metoprolol Retard Viatris

Metoprolol tartrate, the active ingredient in Metoprolol Retard Viatris, is a beta blocker presented as an extended‑release oral tablet for oral use. It is used to lower blood pressure, relieve angina, and improve outcomes after myocardial infarction and in chronic heart failure.

GNH USA supplies Metoprolol Retard Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol tartrate is a selective β1‑adrenergic antagonist indicated for several cardiovascular conditions. - Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output and renin release. - Angina pectoris: lessens myocardial oxygen demand, relieving chest pain during exertion. - Post‑myocardial infarction: lowers the risk of recurrent ischemic events and improves survival. - Chronic heart failure: improves ventricular function and reduces hospitalisation. - Cardiac arrhythmias: controls heart rate in supraventricular tachyarrhythmias.

Metoprolol tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal pain) - Headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute hypotension - Bronchospasm, especially in patients with asthma or COPD - Exacerbation of heart failure - Allergic reactions (rash, angioedema) - Depression or mood changes

Before initiating therapy, clinicians should evaluate cardiovascular status and comorbid conditions. - Cardiovascular assessment: confirm stable heart rate and blood pressure. - Respiratory caution: avoid in uncontrolled asthma or severe COPD. - Renal/hepatic impairment: consider dose adjustment. - Diabetes monitoring: watch for masked hypoglycaemia. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metoprolol tartrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other AV‑node blockers (e.g., verapamil, diltiazem) – risk of profound bradycardia. - Clonidine withdrawal – may cause severe hypertension. - Insulin or oral hypoglycaemics – can mask hypoglycaemic symptoms. - MAO inhibitors – may enhance hypotensive effect. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) – increase metoprolol levels.

Moderate Interactions (Monitor Closely): - Diuretics – additive blood‑pressure lowering. - NSAIDs – may reduce antihypertensive efficacy. - Calcium‑channel blockers – potential for increased bradycardia. - Antithyroid drugs – may alter heart‑rate response. - Certain antidepressants – monitor for enhanced beta‑blockade.